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PRS5  
PREDICTORS OF WILLINGNESS TO QUIT CIGARETTE SMOKING IN A COHORT OF 
ADULTS IN INDIA  
Jadav S, Sansgiry SS 
University of Houston, Houston, TX, USA  
OBJECTIVES: With 182 million smokers living in India, cigarette smoking is a 
serious public health problem associated with severe morbidities and significant 
economic burden. As willingness to quit smoking has been found to be 
associated with smoking cessation; the main objective of the study was to 
examine the predictors of willingness to quit smoking in a cohort of adults in 
India. METHODS: A cross-sectional study was conducted among adults aged ≥18 
years in metropolitan cities in India. Participants completed self-reported 
questionnaire about socio-demographic variables, smoking status, smoking 
status of peers, history of past quit attempts, addiction level and attitudes 
towards smoking. Study cohort consisted of individuals who smoked at least one 
cigarette in the past 30 days. Outcome variable was willingness to quit smoking. 
Variables that were found significant (p<0.05) in bivariate analyses were included 
in multivariate logistic regression models to determine predictors of willingness 
to quit smoking. RESULTS: Out of 761 participants, 469 respondents (61.6 %) were 
smokers and 253 (54%) of smokers were willing to quit smoking. Regression 
showed that higher willingness to quit smoking was associated with group of age 
40-49 years (OR:2.41, 95%CI: 1.19-4.90), religion Muslim (OR:0.46, 95%CI: 0.25-0.83) 
or Christian ( OR: 0.41, 95%CI: 0.22-0.76), close friend (OR:2.23, 95%CI: 1.40-3.57) 
and siblings (OR:3.06, 95%CI: 1.95 - 4.78) being non-smoker , higher number of 
smoking friends (OR:1.85, 95%CI: 1.05-3.24) and previously tried to quit smoking 3 
times (OR:2.30, 95% CI: 1.36 - 3.87) or more than 3 times (OR:22.89, 95%CI: 5.27-
99.32). All reported values are statistically significant (p<0.05). CONCLUSIONS: 
Our study identified significant predictors of willingness to quit smoking among 
a cohort of adults in India. Intervention strategies should be developed 
considering targeted programs to address opportunities for individuals willing to 
quit smoking.  
 
PRS6  
EXCESS RISKS AND COSTS OF INVASIVE PNEUMOCOCCAL DISEASE  
AND PNEUMONIA AMONG US PERSONS WITH UNDERLYING MEDICAL 
CONDITIONS  
Weycker D1, Farkouh R2, Strutton DR3, Edelsberg J4, Shea K5, Pelton S5 
1PAI, Brookline, MA, USA, 2Pfizer, Collegeville, PA, USA, 3Pfizer, Inc., Collegeville, PA, USA, 
4Policy Analysis Inc. (PAI), Brookline, MA, USA, 5Boston University, Boston, MA, USA  
OBJECTIVES: Presence of underlying medical conditions is believed to increase 
risk of pneumococcal disease (PD) across all age groups. However, excess risks of 
PD attributable to specific conditions are not well known in children or adults, 
nor are condition-specific attributable economic costs. METHODS: Using health 
care claims information from ~80 million persons annually, plan members 
during 2007-2010 were stratified into subgroups based on presence of selected 
“at-risk” chronic conditions (eg, heart, lung, and liver disease, asthma, diabetes) 
and “high-risk” immunocompromising conditions (eg, malignancies, HIV, 
chronic renal disease). At-risk and high-risk conditions, and episodes of invasive 
pneumococcal disease (IPD) and all-cause pneumonia (PNE), were identified via 
diagnosis, procedure, and drug codes. Annual PD rates and PD-attributable 
health care costs (2010US$) among at-risk and high-risk persons versus age-
matched healthy counterparts were compared using incidence rate ratios (IRR) 
and cost ratios; corresponding 95% CIs were estimated using Poisson regression 
and nonparametric bootstrapping. RESULTS: Annual rates of IPD and PNE were 
consistently higher among at-risk persons (IRR=3.8 [95% CI 3.5-4.0] and 4.5 [4.5-
4.6]) and high-risk persons (IRR=9.3 [8.6-10.0] and 8.2 [8.2-8.3]) versus their 
healthy counterparts. Rates were notably high for at-risk persons with asthma 
(IRR=3.2 [2.8-3.7] and 4.4 [4.4-4.5]), diabetes (IRR=3.8 [3.5-4.2] and 4.6 [4.5-4.6]), or 
≥2 at-risk conditions (IRR=8.5 [7.8-9.2] and 10.6 [10.6-10.7]). Annual PD-
attributable health care costs totaled $56.1 million per 100,000 at-risk person-
years and $118.9 million per 100,000 high-risk person-years, which were 5.2 [5.1-
5.2] and 11.0 [10.9-11.0] times higher than corresponding costs for healthy 
persons. CONCLUSIONS: Rates and costs of PD are substantially higher among 
persons with certain chronic and immunocompromising conditions versus those 
without any such conditions. Rates and costs for persons with asthma and 
diabetes were especially increased, and rates and costs for individuals with ≥2 
at-risk conditions approached those among persons with high-risk conditions.  
 
PRS7  
THE EFFECT OF SMOKING ON HEALING OF TIBIA FRACTURES: A BAYESIAN 
META-ANALYSIS  
Borgman B1, Stam W2 
1Medtronic Trading Sàrl., Tolochenaz, Switzerland, 2Stam Consulting, Houten, The Netherlands  
OBJECTIVES: To optimize decisions on initial fracture treatment it is of interest 
to identify patients at risk for delayed bone union. The current study aimed to 
estimate the impact of smoking on the rate of union of tibia fractures. 
METHODS: A systematic literature search (1990–2012) was performed using the 
Cochrane library, Medline and Embase to identify studies that evaluated  
the effect of smoking on healing of ‘fresh’ tibia fractures. The endpoint of 
interest was the hazard ratio (HR) of bone union between smokers and  
non-smokers. Reported and calculated HRs were pooled applying a Bayesian 
random effects analysis. RESULTS: Six observational studies were identified all 
reporting favorable time to union for non smokers relative to smokers. One study 
was excluded from the meta-analysis as it did not allow for estimating a HR.  
One study reported an adjusted HR, whereas four other studies reported mean or 
median time to union. For these latter studies, HRs were estimated assuming 
constant hazard rates for bone union from week 7 following surgery.  
The analysis demonstrated that the rate of bone union was delayed in smokers 
relative to non-smokers, mean HR: 0.74, 95% credibility Interval (CrI): 0.65-0.85, 
corresponding to a >99% probability of delayed bone union in smokers, with  
a mean (95% CrI) delay of 3.0 (2.9-3.2) weeks. The current analysis has limitations 
which relate mainly to the observational nature of the included studies as  
well as the distributional assumptions required for estimating HRs. A sensitivity 
analysis excluding 1 study reporting the most favorable results for non- 
smoking still indicated a >99% probability of slower bone union in smokers as 
compared to non-smokers. CONCLUSIONS: The current study indicates that 
patients that smoke are at increased risk for delayed healing of tibial fractures 
and an evaluation of initial adjunctive treatment in these patients may be 
merited.  
 
PRS8  
DOES AN ECZEMA DIAGNOSIS IN CHILDREN UNDER THE AGE OF  
THREE PREDICT A SEVERE ASTHMA DIAGNOSIS: A UK RETROSPECTIVE 
ANALYSIS?  
Naidoo S1, Odeyemi I2 
1Astellas Pharma Europe Ltd, Chertsey, UK, 2Astellas Pharma Europe Ltd., Staines, UK  
There is evidence to suggest that young children with eczema are predisposed  
to developing asthma in their early life and it is proposed that previous eczema 
diagnosis could predict a more severe form of subsequent asthma. Therefore,  
it is vital to consider measures and policies to influence the pathogenesis of this 
disease. OBJECTIVES: To explore whether prescription data can identify those 
eczema patients at greater risk of developing severe asthma as early as possible 
in their atopic disease pathogenesis. METHODS: Using UK prescription data  
from IMS-Disease AnalyzerTM two case-controlled cohorts were extracted and 
analysed. The cohorts consisted of 20,095 and 5,840 patients respectively. 
RESULTS: The odds of a child with eczema having asthma before the age of  
13 were 2.6 times greater (p<0.001; 95% CI 2.5-2.8) than a child who had no 
eczema at the same age. When comparing patients classified as having severe 
eczema, the odds of developing severe asthma before the age of 13 were 1.7 
times greater (p<0.001; 95% CI 1.5-1.9) for children who had eczema before their 
third birthday than those who had no eczema born in the same year.  
The analysis of prescription data were restrictive in the electronic record  
so assumptions and the additional criteria imposed during analysis may have 
introduced bias. CONCLUSIONS: Severity in asthma patients in the UK have  
now come to the forefront of discussion at many levels - patients, health  
care professionals and government. The burden of morbidity of atopic disease 
could be influenced in a downward fashion if greater efforts and resources  
were focused at national level to improve the plight of patients and ensure 
efficient use of the scarce health care resources available. Robust cost-
effectiveness analyses are required to argue the case for expenditure on this 
neglected area.  
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PRS9  
BUDGET IMPACT ANALYSIS OF BALLOON DILATION AND FUNCTIONAL 
ENDOSCOPIC SURGERY – A US PAYER PERSPECTIVE  
Holy C, Ellison J, Schneider C 
Acclarent, Menlo Park, CA, USA  
OBJECTIVES: Legislators, health system administrators, employers and other 
stakeholders are increasingly concerned about growing health care costs. 
Technologies must therefore continue to demonstrate safety and effectiveness 
alongside sound economics. Surgical tools for balloon catheter dilation (BCD) of 
sinus ostia offer an alternative way for surgeons to treat patients with chronic 
rhinosinusitis (CRS) in a tissue-sparing fashion. In some instances, these tools 
are also used alongside rigid instruments during functional endoscopic sinus 
surgery (FESS). BCD has strong safety and effectiveness evidence and allows 
migration of site of care from the operating room (OR) to the physician office. 
However, limited data exist analyzing the economic impact of the technology on 
CRS cost of care. METHODS: A budget impact analysis (BIA) was developed to 
determine the potential impact of BCD on health care costs. The analysis was 
performed from the viewpoint of the US payer and actual payments for health 
care services were included in the model, in lieu of costs. Inputs included 
frequency of service and payments for preoperative care and surgery; frequency, 
type of visits and procedures and payments for postoperative care (including 
debridements and related procedures), and payments and frequency of 
reoperations and exacerbations. Clinical inputs were based on published 
literature and analyses of claims databases from Marketscan, using a cohort with 
at least 2 years of continuous enrollment post-index. Monte Carlo simulations 
were conducted to determine impact of uncertainty on final estimates. RESULTS: 
For 1,400 surgical cases (expected surgical volume within a 1 million population), 
the total cost of care over 2 years assuming current treatments was estimated at 
US$ 14.23±0.26 million. Assuming however that 20% patients transition from 
FESS to BCD and 10% thereof would be treated in the office versus the OR, total 
cost would reach US$13.92±0.22 million. CONCLUSIONS: For well selected 
patients, shifting site of care from the OR to the office, along with the less-
invasive BCD technology versus FESS, shows trends of cost favorability over a 2-
year time horizon.  
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ESTIMATING THE BUDGET IMPACT OF ADDING OMALIZUMAB TO STANDARD 
THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ALLERGIC ASTHMA 
FROM PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL  
Suzuki C, Santoni NB, Silva NL 
Novartis Biociências S.A., São Paulo, Brazil  
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OBJECTIVES: To estimate the budget impact of adding omalizumab to standard 
therapy (ST) in patients with uncontrolled severe allergic asthma, from the 
perspective of the Brazilian private health care system, over a 5-year time 
horizon. METHODS: A budget impact model was developed to calculate the 
budget impact for Brazil, based on local epidemiological and drug cost data. The 
eligible population was based on the following inputs: 2013 population estimate 
(age ≥6 years): 183 million; prevalence of asthma: 10%; proportion of patients 
diagnosed and receiving treatment: 6.5%; percentage with allergic asthma: 69%; 
percentage with immunoglobulin E (IgE) ≥30 IU/mL: 78.7%; percentage with 
uncontrolled, severe disease: 2.4%; proportion of population using the private 
health care system and medications: 25.1%. For the following years, an annual 
population growth rate of 1.17% was assumed. Average doses, resource 
utilization per exacerbation and proportion of patients who respond to 
omalizumab were obtained from the INNOVATE trial. Direct costs, including 
omalizumab purchase and the costs of health care consumption related to 
exacerbations and routine visits. These costs were calculated from the 
perspective of the private health care payer. Omalizumab uptake was assumed 
to be 17%, 35%, 55%, 75% and 95% of eligible population for years 1 to 5, 
respectively. RESULTS: The number of patients eligible for add-on omalizumab 
therapy that met the eligibility criteria was estimated to be around 3,887 in the 
first year. The annual budget impact of omalizumab was approximately BRL25 
million, BRL50 million, BRL77 million, BRL104 million and BRL131 million for 
years 1 to 5, respectively (BRL1=USD0.492). CONCLUSIONS: The budget impact 
for the private health care system in Brazil of adding omalizumab to ST was 
approximately BRL131 million at the end of year-5. Considering that the total 
population using the private health care system in Brazil is around 45.4 million, 
this represents a relatively small impact on the payer’s budget, of BRL2.90 per 
beneficiary.  
 
PRS11  
SYSTEMATIC REVIEW OF THE LITERATURE AND COST MINIMIZATION  
AND BUDGET IMPACT ANALYSES OF THE TREATMENT OF CHRONIC 
OBSTRUCTIVE PULMONARY DISEASE (COPD) WITH INHALED CORTICOIDS IN 
BRAZIL  
Fonseca M1, Decimoni TC2, Santos AM2, Araújo GTB2 
1Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil, 2Axia.Bio Consulting, 
São Paulo, Brazil  
OBJECTIVES: The prevalence of COPD in Brazil is estimated in 15,8% and it is the 
fourth cause of hospitalization a in the Brazilian public health system (SUS) in 
the last 10 years. Until recently only the short-action and long-action β2-agonists 
were distributed to COPD patients by SUS. The aim of this study was to 
determine the expected consequences on the cost and effectiveness and the 
budgetary impact of the recent introduction in SUS of budesonide and 
beclomethasone for the treatment of COPD patients. METHODS: Systematic 
review of the literature and development of a decision analytic model to 
demonstrate the immediate response to treatment with inhaled steroids and 
project the results in terms of effectiveness and cost based on current knowledge 
of the natural history of the disease. The analysis was performed for a 
hypothetical cohort of adults with forty or more years with COPD GOLD stage II, 
III or IV. The primary perspective of the study was SUS. Data sources were the 
medical literature, official published prices of SUS for medicines and DATASUS 
(SUS database). RESULTS: Corroborating the results of other systematic reviews 
we also did not detect differences in efficacy and safety between budesonide and 
beclomethasone therefore we performed a cost-minimization analysis. Both 
steroids reduced the exacerbation rate in about 40%. The annual costs of the 
treatment with budesonide and beclomethasone were 714,29 and 786,77, 
respectively. The parameter that led to greater variation in the model was the 
cost of hospitalizations with ICU stays. The projected budget impact for 
introduction of inhaled corticoids (50%/50%) for COPD treatment in 2013 is about 
R$345 million reais. CONCLUSIONS: There are no differences in efficacy and 
safety between the studied inhaled steroids. To achieve about 40% reduction in 
the exacerbation rate the budget impact for SUS in 2013 would be of 
approximately R$345 million reais.  
 
PRS12  
CLINICAL AND ECONOMIC BURDEN OF CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE IN VETERAN PATIENTS IN THE UNITED STATES: A REAL-WORLD 
EVALUATION  
Wang L1, Huang A1, Baser O2 
1STATinMED Research, Dallas, TX, USA, 2STATinMED Research/The University of Michigan, 
Ann Arbor, MI, USA  
OBJECTIVES: To evaluate the clinical and economic burden of chronic 
obstructive pulmonary disease (COPD) in the U.S. veteran population. METHODS: 
Patients diagnosed with COPD (International Classification of Disease 9thRevision 
Clinical Modification [ICD-9-CM] diagnosis codes 490.xx, 491.xx, 492.xx, 494.xx, 
495.xx, 496.xx) were included in this retrospective study (October 1, 2005 - May 
31, 2012) conducted using the Veterans Health Administration (VHA) Medical 
SAS Datasets. Health care resource utilization and costs were assessed for the 
12-month follow-up period. Patients' clinical and discharge statuses were 
examined for the 12-month baseline period. Means and standard deviations 
were provided for continuous variables. Numbers and percentage were provided 
for categorical variables. All descriptive statistical analyses were performed 
using SAS v9.3 software. RESULTS: Among all study patients diagnosed with 
COPD (772,898), major comorbidities during the baseline period included 
hypertension (27.9%), depressive disorder (6.72%), chronic ischemic heart disease 
(5.18%) and shortness of breath (4.73%). The most common medications 
prescribed within 60 days of disease identification were simvastatin (27.45%), 
lisinopril (20.63%), omeprazole (19.47%) and aspirin (12.19%). In the 12-month 
follow-up period, 49.61% of patients were prescribed short-acting b-agonists 
(SABAs) while only 60 patients were prescribed long-acting b-agonists (LABAs). 
Outpatient visits (99.75%) occurred more frequently than inpatient visits 
(22.28%). Inpatient ($8,420), outpatient ($8,584) and pharmacy costs ($1,746) 
combined for a total expenditure of $18,750. CONCLUSIONS: Patients were 
prescribed simvastatin, lisinopril and omeprazole more often within 3 months 
after disease identification than other medications. Within 1-year post-
diagnosis, SABAs were prescribed more often than LABAs as a treatment for 
COPD.  
 
PRS13  
HOSPITALIZATION COSTS RELATED TO PULMONARY HYPERTENSION  
(PH) AMONG MEDICARE ADVANTAGE OR COMMERCIALLY INSURED  
PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) IN THE UNITED 
STATES  
Lacey M1, Hunsche E2, Buzinec P1, Drake W3, Nagao M3, Régulier E2 
1OptumInsight, Eden Prairie, MN, USA, 2Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, 
3Actelion Pharmaceuticals US Inc., South San Francisco, CA, USA  
OBJECTIVES: Health care cost data for pulmonary arterial hypertension (PAH) are 
scarce, especially for important morbidity events like hospitalizations, owing to 
the absence of a unique ICD-9-CM code. This study assessed inpatient costs and 
length of stay (LOS) among US patients with PAH. METHODS: A retrospective 
analysis was performed using data (January 2007–December 2011) from adult 
enrollees with Commercial or Medicare Advantage with prescription drug 
coverage from a large health plan. PAH patients were identified based on both ≥1 
medical claim with an ICD-9-CM code for primary pulmonary hypertension (PH) 
(416.0) or other chronic pulmonary heart disease (416.8), and ≥1 pharmacy claim 
for a medication indicated for PAH or frequently used in PAH. Patients had to 
have ≥365 days of enrollment prior to index date (study inclusion) and 180 days 
during follow-up. Discharge diagnoses being unavailable, the principal diagnosis 
for each hospitalization was defined as the most frequent primary diagnosis on 
that hospitalization's facility claims. Total hospitalization costs (inflated to 2011 
USD using the CPI-U) and LOS, stratified by payer (excluding dual eligibility) and 
principal diagnosis, were analyzed with descriptive statistics. RESULTS: The 4009 
PAH patients (52% female, mean±SD age 60±14 years) incurred 5582 
hospitalizations. Hospitalization cost was $34,123±107,005 (mean±SD), and was 
nearly 3 times higher for hospitalizations with Commercial ($46,118±135,137, 
n=3322) than Medicare Advantage coverage ($16,319±30,046, n=2244). Average 
cost was higher for hospitalizations with a principal diagnosis of PH (416.0 or 
418.6) than other principal diagnoses ($49,722±181,878, n=878 vs $31,211± 85,821, 
n=4704). Average LOS was 11.7±20.8 days, and was longer for hospitalizations 
with Medicare than Commercial coverage (12.8±21.2 vs 10.9±20.4 days), and for 
hospitalizations with PH as principal diagnosis compared with other principal 
diagnoses (15.0±30.5 vs 11.1±18.3 days). CONCLUSIONS: Long durations and high 
incurred costs for PH-related hospitalizations reveal the severe morbidity, health 
care, and patient burden of PAH.  
 
PRS14  
ASTHMA-RELATED HEALTH CARE UTILIZATION IN PATIENTS WITH ORAL 
CORTICOSTEROID-DEPENDENT ASTHMA  
Buck PO1, Buatti Small M1, Hankin CS2, Bronstone A2, Wang Z2, Gopalan G1, Lepore M1 
1Teva Pharmaceuticals, Frazer, PA, USA, 2BioMedEcon, LLC, Moss Beach, CA, USA  
OBJECTIVES: Severe, poorly-controlled asthma affects a minority of asthma 
patients but accounts for a disproportionately large amount of asthma-related 
medical expenditures. Based on 2007 NIH (NHLBI EPR-3) guidelines, oral 
corticosteroids (OCS) are recommended therapy for step 6 management of severe 
persistent asthma. We sought to better understand asthma-related health care 
utilization in patients who require frequent OCS. METHODS: We examined 
Thomson Reuters MarketScan claims data (2006-2010) to identify patients aged 
≥12 years, continuously enrolled for ≥24 months, with OCS-dependent asthma, 
defined as ≥3 30-day OCS fills over a 12-month period and a primary asthma 
diagnosis (ICD-9 493) within 12 months of the first OCS fill. Excluded were 
patients with COPD including emphysema, cystic fibrosis, acute respiratory 
failure, and 29 other conditions that may require frequent OCS. Asthma-related 
health care utilization was examined during the 12-month period following 
patients’ first OCS fill. RESULTS: Among the 10,319 patients meeting study 
criteria, 6,941 (67.3%) were female; the mean (SD) age at first OCS fill was 57.9 
(15.9). The most common comorbid diagnoses were allergic rhinitis (n=1,507; 
14.6%), chronic sinusitis (n=1,236; 12.0%), pneumonia (n=1,066; 10.4%), and 
gastroesophageal reflux disease (n=1,036; 10.0%). During 12-month follow-up, 
patients received a mean (SD) of 6.2 (3.6) OCS fills. OCS was used in conjunction 
with at least 2 additional asthma medications in 6,671 (64.6%) patients, but only 
5,428 (52.6%) received concomitant guideline-recommended treatment with both 
an inhaled corticosteroid and long-acting beta agonist. Asthma-related 
hospitalizations and emergency department (ED) visits were experienced by 6.5% 
(n=673) and 6.9% (n=712) of patients, respectively. The mean (SD) number of 
asthma-related hospitalizations was 1.4 (1.5), with an average stay of 4.6 days; 
the mean (SD) number of asthma-related ED visits was 1.2 (0.5). CONCLUSIONS: 
Despite frequent use of OCS and additional asthma medications, this population 
of patients with asthma experienced high levels of asthma-related 
hospitalizations and ED visits.  
 
PRS15  
COPD PREVALENCE AND COSTS VALUE IN UKRAINE  
Zalis'ka O1, Tolubaiev V1, Kacheray Y1, Tolubaieva V2 
1Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, 2Med Garant, Kiev, Ukraine  
OBJECTIVES: Chronic obstructive pulmonary disease is a very important problem 
for health systems of different countries trough out the world. For Ukraine as for 
